09:22 AM EDT, 03/17/2026 (MT Newswires) -- Humacyte ( HUMA ) said Tuesday it submitted a marketing authorization application to the Israeli health ministry for its bioengineered tissue implant designed for arterial trauma repair.

The biotechnology developer is also pursuing a mechanism to make the product available across individual hospitals within the country prior to formal regulatory approval, the company said.

It is designed to save critical surgical time during emergency situations where traditional vein harvesting is not feasible, Humacyte ( HUMA ) said.

The company also said it is preparing to expand the availability of the tissue-engineered vessel into additional Middle Eastern countries.

Shares of the company were up 1.7% in Tuesday premarket activity.